1
Waclaw J Rzeszotarski, Babu J Mavunkel: Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists. Nova Pharmaceutical Corporation, Breneman & Georges, December 26, 1989: US04889860 (84 worldwide citation)

A potent, selective opioid receptor agonist or antagonist exhibiting properties useful for a longacting analgesic or opiate abuse treatment agent or appetite suppressant having the general formula: ##STR1## wherein R is methyl, cyclopropylmethyl or allyl, and R.sub.1 is an unsubstituted or substitut ...


2
Waclaw J Rzeszotarski, Babu J Mavunkel: Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists. Nova Pharmaceutical Corporation, Breneman & Georges, July 26, 1988: US04760069 (75 worldwide citation)

A potent, selective opioid receptor agonist or antagonist exhibiting properties useful for a long-acting analgesic or opiate abuse treatment agent or appetite suppressant having the general formula: ##STR1## wherein R is methyl, cyclopropylmethyl or allyl, and R.sub.1 is an unsubstituted or substitu ...


3
Waclaw J Rzeszotarski, Robert L Hudkins, Maria E Guzewska: Antagonists of specific excitatory amino acid neurotransmitter receptors. Nova Pharmaceutical Corporation, Breneman Georges Hellwege & Yee, April 14, 1987: US04657899 (52 worldwide citation)

The invention pertains to novel, potent anticonvulsants, analgesics and cognition enhancers achieving their action through the antagonism of specific excitatory amino acid neurotransmitter receptors. In particular, the invention is directed to .omega.-[2-phosphonoalkyleneyl)phenyl]-2-aminoalkanoic a ...


4
Waclaw J Rzeszotarski, Donald J Kyle: Antagonists of specific excitatory amino acid neurotransmitter receptors having increased potency. Nova Pharmaceutical Corporation, Breneman & Georges, August 2, 1988: US04761405 (26 worldwide citation)

The invention pertains to novel, potent anticonvulsants, analgesics, cognition enhancers and neuroprotectants achieving their action through the antagonism of specific excitatory amino acid neurotransmitter receptors. In particular, the invention is directed to .omega.-[2-(phosphonoalkylenyl)-cycloa ...


5
Waclaw J Rzeszotarski, Vicki H Audia, Moshe Weitzberg: 1-azabicyclo[2.2.2]octan-3-yl 2-aryl-3-azacyclo-2-hydroxypropionates and their quaternary salts. Marion Laboratories, Dewey Ballantine Bushby Palmer & Wood, June 27, 1989: US04843074 (25 worldwide citation)

Novel 1-azabicyclo[2.2.2]octan-3-yl 2-aryl-3-azacyclo-2-hydroxypropionates and their quaternary salts and their use as antimuscarinic agents having antisecretory activity selective for the gastrointestinal tract are disclosed. The compounds have the formula: ##STR1## wherein: X=H, halogen, lower alk ...


6
Waclaw J Rzeszotarski, Ronald H Erickson: Method of treating bronchoconstriction with 1,3-unsymmetrical straight chain alkyl-substituted 8-phenylxanthines. Marion Merrell Dow, Theresa M Gillis, July 16, 1991: US05032593 (14 worldwide citation)

1,3-Alkyl substituted-8-phenylxanthines in which the straight chain alkyl substituents are different and pharmaceutically acceptable salts of such compounds are disclosed. Preferred compounds have 1-n-propyl-3-methyl and 1-methyl-3-n-propyl substituents. The compounds are potent bronchodilators.


7
Waclaw J Rzeszotarski, Maria E Guzewska, Suzanne R Ellenberger, Lisa H Conti, John W Ferkany, Donald J Kyle: Antagonists of specific excitatory amino acid receptors as neuroprotectants and anxiolytics. Nova Pharmaceutical Corporation, Vincent L Fabiano, September 17, 1991: US05049555 (12 worldwide citation)

The invention pertains to a method and pharmaceutical compositions for treating, preventing or reducing neurodegeneration associated with chronic central nervous system or hypoxic, ischemic and hypoglycemic injury to the central nervous system and for the treatment of anxiety through the use of 2-am ...


8
Waclaw J Rzeszotarski, Roger N Hiner, Scott W Feeney: 8-(oxo-substituted cycloalkyl)xanthines. Marion Merrell Dow, Theresa M Gillis, December 29, 1992: US05175290 (11 worldwide citation)

1,3-Substituted-8-(oxo-substituted cycloalkyl)xanthines and pharmaceutically acceptable salts of such compounds are disclosed. Preferred compounds include the cis and trans isomers of 1,3-dipropyl-8-(3-hydroxycyclopentyl)xanthine and the cis and trans isomers of 1,3-dipropyl-8-(4-hydroxycyclohexyl)x ...


9
William C Eckelman, Richard C Reba, Waclaw J Rzeszotarski, Raymond E Gibson: Gamma-emitting receptor-binding 3-quinuclidinyl glycolates; methods of preparation thereof and imaging and assay methods utilizing same. Research Corporation, Scully Scott Murphy & Presser, February 14, 1984: US04431627 (10 worldwide citation)

Compounds of the formula: ##STR1## wherein R is aryl, alkyl, cycloalkyl, phenyl, cyclopentyl, cyclohexyl, a ligand containing Tc-99m in chelated form or a ligand capable of chelating Tc-99m;


10
Waclaw J Rzeszotarski, Rickey P Hicks, Ronald H Erickson: 8-arylxanthines. Marion Laboratories, Dewey Ballantine Busby Palmer & Wood, November 8, 1988: US04783530 (9 worldwide citation)

1,3-alkylsubstituted-8-(3,4-,3- or 4-substituted phenyl)xanthines and pharmaceutically acceptable salts of such compounds are disclosed. The 3-substituents are hydrogen, dimethylaminomethyl, or 2,3-dihydroxypropyloxy. The 4-substituents are selected from hydroxy, cyano, --NHCON(R.sub.5).sub.2, --C(. ...